A. Craig Lockhart, M.D., MHS, FASCO, is the director of the Division of Hematology & Oncology in the College of Medicine at the Medical University of South Carolina (MUSC) and associate director for Clinical Science at the MUSC Hollings Cancer Center.
As the Grace E. De Wolff Endowed Chair in Medical Oncology, his research specialty is gastrointestinal cancers, and he has been a principal investigator on more than 100 Phase I/II and III trials.
Prior to joining MUSC, Dr. Lockhart was on the faculty and in leadership roles at the University of Miami, Miller School of Medicine, Washington University in St. Louis/Siteman Cancer Center, and at Vanderbilt University/Vanderbilt-Ingram Cancer Center.
Dr. Lockhart has been conducting early-phase clinical trials for over 20 years. His specific research interests are developing and conducting Phase I/II clinical trials of novel therapeutics applied to gastrointestinal cancers. In treating these cancers, he aims to incorporate novel agents or molecular/genetic-based treatments into therapeutic trials in the pursuit of personalized cancer care. He has developed and led multi-institutional clinical trials involving the treatment of GI tumors through national cooperative groups as well as investigator-initiated studies. He has been an investigator and co-investigator on individual grants, on successful SPORE grant applications, and on successful multi-institutional UM1 grant applications.
Dr. Lockhart has also served on several committees for the American Society of Clinical Oncology (ASCO), including the scientific and career development committees. He has been a member of the National Comprehensive Cancer Network (NCCN) guidelines committee for gastric and esophageal cancers. He also serves as faculty at the ASCO/American Association for Cancer Research (AACR) Methods in Clinical Cancer Research Workshop, mentoring fellows and junior faculty on the development of gastrointestinal cancer therapeutic protocols.
Dr. Lockhart graduated from the University of Texas Southwestern Medical School at Dallas in 1993. He completed residency training at Barnes Hospital at Washington University, fellowship training in hematology/oncology at Duke University, and a fellowship in drug development at GlaxoSmithKline in the North Carolina Research Triangle Park. He also earned a Master of Health Science degree in clinical trials at Duke University and completed his Bachelor of Science in Biology at Rice University.